Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders



Status:Recruiting
Conditions:Infectious Disease, Hematology
Therapuetic Areas:Hematology, Immunology / Infectious Diseases
Healthy:No
Age Range:Any
Updated:1/26/2019
Start Date:May 2015
End Date:January 2024
Contact:Barbara Degar, MD
Email:bdegar@partners.org
Phone:617-632-5186

Use our guide to learn which trials are right for you!

Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders

This research study is evaluating a drug called clofarabine as a possible treatment for
Langerhans Cell Histiocytosis (LCH) and and other histiocytic disorders.

This research study is a Phase II clinical trial. Phase II clinical trials test the
effectiveness of an investigational intervention, to learn whether the drug works in treating
a specific disease, in this case, clofarabine to treat LCH.

"Investigational" means that the intervention is still being studied. It also means that the
FDA (the U.S. Food and Drug Administration) has not yet approved clofarabine for your
disease.

Clofarabine is a chemotherapy drug that has been used and is approved by the FDA for the
treatment of leukemia in children and adults. Information from other research studies
suggests that this drug may also be effective in participants with LCH and other histiocytic
disorders.

Inclusion Criteria:

- Prior diagnosis of Langerhans Cell Histiocytosis (stratum 1) or LCH-related disorder
(stratum 2) established by standard diagnostic criteria and confirmed histologically.

- Evidence of active disease (histological confirmation of reactivation or progression
is not required).

- Performance Score > 70% (use Lansky score for age < 16 and Karnofsky score for age =
>16).

- Patients of all ages will be eligible.

- Provide signed written informed consent.

- In stratum 1, patients must have failed one prior systemic chemotherapy regimen. In
stratum 2, RDD patients must have failed treatment with corticosteroid. ECD patients
who have confirmed BRAF V600E mutation must have failed treatment with a BRAF
inhibitor or are not considered to be eligible for such treatment.

- There is no limitation of amount or the type of prior therapy or drugs.

- Female patients of childbearing potential must have a negative serum pregnancy test
within 14 days prior to enrollment. Male and female patients must use an effective
contraceptive method during the study and for a minimum of 6 months after study
treatment.

- Capable of understanding the investigational nature, potential risks and benefits of
the study, and able to provide valid informed consent.

- Participants must have adequate marrow functions as defined below, except those with
involvement of hematopoietic system for whom these criteria can be waived:

- Absolute neutrophil count ≥ 750 cells/µL

- Platelets ≥75,000/µL

- Participants must have adequate organ functions as defined below:

- Total bilirubin ≤ 2.5x institutional upper limit of normal

- AST (SGOT)/ALT (SGPT) < 2.5 X institutional upper limit of normal unless it is
related to involvement by LCH

- Adequate renal function defined as:

- Pediatric Population (patients < 18 years): Creatinine within normal limits or
calculated creatinine clearance greater than or equal to 90 ml/min/1.73 m2 as
calculated by the Schwartz formula for estimated glomerular filtration rate (GFR)
where GFR (ml/min/1.73 m2) = k x Height (cm)/serum creatinine (mg/dl). k is a
proportionality constant which varies with age and is a function of urinary
creatinine excretion per unit of body size; 0.45 up to 12 months of age; 0.55
children and adolescent girls; and 0.70 adolescent boys.

- Adult Population (patients >= 18 years): Serum creatinine less than or equal to
1.0 mg/dL; if serum creatinine >1.0 mg/dL, then the estimated glomerular
filtration rate (GFR) must be >60 mL/min/1.73 m2 as calculated by the
Modification of Diet in Renal Disease equation where Predicted GFR (ml/min/1.73
m2) = 186 x (Serum Creatinine)-1.154 x (age in years)-0.203 x (0.742 if patient
is female) x (1.212 if patient is black), where serum creatinine is measured in
mg/dL.

- Alkaline phosphatase ≤ 2.5 x institutional upper limit of normal

Exclusion Criteria:

- Participants who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for
nitrosoureas or mitomycin C) prior to entering the study or those who have not
recovered from adverse events due to agents administered more than 2 weeks earlier.
Corticosteroid treatment is allowed.

- Participants may not be receiving any other investigational agents targeting
Histiocytosis.

- Clofarabine is excreted primarily by the kidneys. Therefore, drugs with known renal
toxicity (e.g.vancomycin, amphotericin B, acyclovir, cyclosporin, methotrexate,
tacrolimus) should be avoided to the extent possible during the 5 days of clofarabine
treatment in each cycle or, if required, administered cautiously and with close
monitoring.

- Use of alternative medications (e.g., herbal or botanical that could interfere with
clofarabine) is not permitted during the entire study period.

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

- Pregnant women are excluded from this study because clofarabine is a nucleoside analog
with the potential for teratogenic or abortifacient effects. Because there is an
unknown but potential risk of adverse events in nursing infants secondary to treatment
of the mother with clofarabine, breastfeeding should be discontinued if the mother is
treated with clofarabine. These potential risks may also apply to other agents used in
this study.

- Individuals with a history of a different malignancy are ineligible except for the
following circumstances. Individuals with a history of other malignancies are eligible
if they have been disease-free for at least 5 years and are deemed by the investigator
to be at low risk for recurrence of that malignancy. Individuals with the following
cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer
in situ, and basal cell or squamous cell carcinoma of the skin.

- Patients with a history of prior hematopoietic stem cell transplantation (HSCT),
elevated conjugated serum bilirubin at study entry, uncontrolled systemic fungal,
bacterial, or other infection, a history of hepatitis B or C infection or a history of
cirrhosis.

- Individuals who are known to be HIV-positive on combination antiretroviral therapy are
ineligible because of the potential for pharmacokinetic interactions with clofarabine.
In addition, these individuals are at increased risk of lethal infections when treated
with marrow-suppressive therapy. Appropriate studies will be undertaken in
participants receiving combination antiretroviral therapy when indicated.
We found this trial at
13
sites
262 Danny Thomas Pl
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Patrick Campbell, MD
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
?
mi
from
Memphis, TN
Click here to add this to my saved trials
185 Cambridge Street
Boston, Massachusetts 02114
617-724-5200
Phone: 617-726-2737
?
mi
from
Boston, MA
Click here to add this to my saved trials
3333 Burnet Avenue # Mlc3008
Cincinnati, Ohio 45229
 1-513-636-4200 
Phone: 513-803-1631
Cincinnati Children's Hospital Medical Center Patients and families from across the region and around the...
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
4650 Sunset Blvd
Los Angeles, California 90027
 (323) 660-2450
Phone: 323-361-5639
Childrens Hospital Los Angeles Children's Hospital Los Angeles is a 501(c)(3) nonprofit hospital for pediatric...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1 Gustave L Levy Pl # 271
New York, New York 10029
 (212) 241-6500
Phone: 212-241-7022
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
?
mi
from
New York, NY
Click here to add this to my saved trials
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Principal Investigator: Barbara Degar, MD
Phone: 617-632-5186
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Barbara Degar, MD
Phone: 617-632-6633
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
6621 Fannin St
Houston, Texas 77030
(832) 824-1000
Phone: 832-822-4890
Texas Children's Hospital Texas Children's Hospital, located in Houston, Texas, is a not-for-profit organization whose...
?
mi
from
Houston, TX
Click here to add this to my saved trials
1 Children's Way
Little Rock, Arkansas 72202
(501) 364-1100
Phone: 501-364-1494
Arkansas Children's Hospital Arkansas Children's Hospital (ACH) is the only pediatric medical center in Arkansas...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Philadelphia, Pennsylvania
Phone: 215-590-2821
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
1919 E Thomas Rd
Phoenix, Arizona 85006
(602) 933-1000
Phone: 602-933-0920
Phoenix Children's Hospital Phoenix Children's Hospital has provided hope, healing, and the best healthcare for...
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
505 Parnassus Ave
San Francisco, California 94143
(415) 476-1000
Phone: 415-476-3831
University of California, San Francisco Medical Center UCSF Medical Center is recognized throughout the world...
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
111 Michigan Ave NW
Washington, District of Columbia
(202) 476-5000
Childrens National Medical Center As the nation’s children’s hospital, the mission of Children’s National Medical...
?
mi
from
Washington,
Click here to add this to my saved trials